Global Chronic Plaque Psoriasis Therapeutics Market Size By Type (Clinical, Non-Clinical), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Chronic Plaque Psoriasis Therapeutics Market was valued at USD 21.7 billion in 2023 and is projected to surpass USD 40.2 billion by 2031, growing at a CAGR of 8.1% during the forecast period from 2023 to 2031. The market's growth is driven by the increasing prevalence of chronic plaque psoriasis worldwide, advancements in biologic therapies, and rising awareness of psoriasis as a systemic disease with significant comorbidities. As the most common form of psoriasis, chronic plaque psoriasis affects millions globally, prompting ongoing innovation in targeted therapies and personalized medicine to improve outcomes and quality of life.

Drivers:

1. Increasing Prevalence of Chronic Plaque Psoriasis:

Rising global incidence rates of psoriasis, especially in developed countries, are fueling demand for more effective and long-lasting treatment options. Growing awareness and diagnosis rates contribute to the expanding patient population seeking therapeutic interventions.

2. Advancements in Biologic Therapies:

Recent years have seen a surge in biologics targeting specific immune pathways such as IL-17, IL-23, and TNF-α. These drugs offer significant clinical benefits, including reduced relapse rates and improved skin clearance, which is enhancing their adoption.

3. Growing Awareness and Access to Treatment:

Patient advocacy groups, digital platforms, and public health campaigns are improving awareness about psoriasis management. Combined with better healthcare access, especially in emerging markets, this is driving market growth.

Restraints:

1. High Cost of Biologic Treatments:

Despite their effectiveness, biologics are expensive, limiting access for uninsured patients and placing a financial burden on healthcare systems. This is a major constraint in low- and middle-income countries.

2. Side Effects and Long-Term Safety Concerns:

Biologic therapies may lead to infections, malignancies, or autoimmune issues with prolonged use. These safety concerns can hinder patient compliance and restrict broader adoption.

Opportunity:

1. Expansion in Emerging Markets:

Improved healthcare infrastructure, rising disposable incomes, and increasing government initiatives in countries like India, China, and Brazil present strong growth opportunities for chronic plaque psoriasis therapeutics.

2. Development of Novel Oral and Topical Agents:

The pipeline of non-biologic systemic and topical therapies is expanding, aiming to offer comparable efficacy with fewer side effects and at lower costs—opening new market segments.

3. Personalized Medicine and Biomarker Research:

Increasing focus on personalized treatment approaches based on genetic and immunological profiles is paving the way for next-generation targeted therapies.

Market by System Type Insights:

Based on therapeutic class, Biologics held the largest share of the market in 2023 due to their superior efficacy and longer duration of disease remission. IL-17 and IL-23 inhibitors like Secukinumab and Guselkumab continue to dominate the space. Meanwhile, the Topical Therapy segment is expected to grow steadily among patients with mild-to-moderate disease severity, especially where systemic treatments are not necessary.

Market by End-use Insights:

By end-use, Hospitals & Specialty Clinics represented the largest market share in 2023, accounting for over 50% of revenue due to the preference for biologic administration under medical supervision. The Retail Pharmacies segment is also growing, driven by the increasing availability of oral and topical formulations and improved patient follow-up programs.

Market by Regional Insights:

In 2023, North America led the market with the highest revenue share, driven by high disease prevalence, favorable reimbursement policies, and early adoption of biologics. However, Asia-Pacific is projected to witness the fastest growth rate through 2031, fueled by a rising patient base, growing healthcare expenditure, and the entry of biosimilars and generics into the market.

Competitive Scenario:

Key players in the Global Chronic Plaque Psoriasis Therapeutics Market include AbbVie Inc., Johnson & Johnson, Novartis AG, Eli Lilly and Company, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Bristol Myers Squibb, and Biogen Inc. These companies are investing heavily in R&D, expanding their product pipelines, and focusing on regulatory approvals and strategic collaborations. For instance:

In 2023, Eli Lilly received expanded approval for Taltz® (ixekizumab) for pediatric plaque psoriasis in multiple regions.

In 2024, UCB launched Bimzelx® (bimekizumab) in the U.S. market, offering dual IL-17A and IL-17F inhibition for enhanced therapeutic effect.

Amgen and AstraZeneca partnered to explore combination immunotherapies for resistant cases of plaque psoriasis.

Scope of Work – Global Chronic Plaque Psoriasis Therapeutics Market

Report Metric Details

Market Size (2023) USD 21.7 billion

Projected Market Size (2031) USD 40.2 billion

CAGR (2023–2031) 8.1%

Key Segments by Therapeutic Class Biologics, Oral Systemics, Topical Agents

Key Segments by End-use Hospitals & Specialty Clinics, Retail Pharmacies

Leading Region North America

Growth Drivers Increasing prevalence, biologic innovation, treatment access

Opportunities Emerging markets, personalized medicine, novel therapies

Key Market Developments:

January 2023: Novartis received FDA breakthrough designation for a next-gen oral IL-17A inhibitor for moderate-to-severe psoriasis.

August 2023: AbbVie launched a real-world outcomes platform to track patient responses to Skyrizi® and Humira®.

March 2024: Biogen announced clinical trial initiation for a new biosimilar targeting plaque psoriasis with enhanced delivery technology.

FAQs:

1) What is the current market size of the Chronic Plaque Psoriasis Therapeutics Market?

The market was valued at USD 21.7 billion in 2023.

2) What is the major growth driver of the Chronic Plaque Psoriasis Therapeutics Market?

Advancements in biologic therapies and rising global disease prevalence are the primary growth drivers.

3) Which is the largest region during the forecast period in the Chronic Plaque Psoriasis Therapeutics Market?

North America leads the market, supported by early adoption and robust reimbursement systems.

4) Which segment accounted for the largest market share in Chronic Plaque Psoriasis Therapeutics Market?

The Biologics segment held the largest share in 2023.

5) Who are the key market players in the Chronic Plaque Psoriasis Therapeutics Market?

Major players include AbbVie, Novartis, Johnson & Johnson, Amgen, Eli Lilly, and UCB.